Atlas Trials

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Clinical trial NCT05828589 · TERMINATED

Trial details

NCT number
NCT05828589
Sponsor
BeOne Medicines
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaRelapsed Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRelapsed Follicular LymphomaRelapsed Marginal Zone LymphomaRelapse Diffuse Large B Cell LymphomaRelapsed Small Lymphocytic LymphomaRefractory Follicular LymphomaRefractory Marginal Zone LymphomaRefractory Small Lymphocytic LymphomaRichter Transformation
Start date
2023-06-20
Primary completion
2026-06-08
Enrollment
51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.